Irritable bowel syndrome: The burden and unmet needs in Europe

被引:74
作者
Quigley, E. M. M. [1 ]
Bytzer, P.
Jones, R.
Mearin, F.
机构
[1] Cork Univ Hosp, Alimenatary Pharmabiot Ctr, Dept Med, Cork, Ireland
[2] Glostrup Univ Hosp, Dept Med Gastroenterol, Copenhagen, Denmark
[3] Kings Coll London, GKT Dept Gen Practice & Primary Care, London WC2R 2LS, England
[4] Ctr Med Teknon, Inst Funct & Motor Digest Disorders, Barcelona, Spain
关键词
Europe; healthcare burden; irritable bowel syndrome; quality of life;
D O I
10.1016/j.dld.2006.05.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Irritable bowel syndrome affects approximately 10-15% of the European population, although prevalence rates vary depending on the classification used and the country surveyed. This may be due to differences in patterns of medical care and diagnosis of the condition. Up to 70% of individuals with irritable bowel syndrome may not have been formally diagnosed. The disorder affects 1.5-3 times as many women as men and poses a significant economic burden in Europe, estimated at EURO700--EURO1600 per person per year. It also reduces quality of life and is associated with psychological distress, disturbed work and sleep, and sexual dysfunction. It is a chronic disorder, which affects many individuals for more than 10 years. Most patients are managed in primary care, although some are referred to gastroenterologists and other specialists. Patients with irritable bowel syndrome undergo more abdomino-pelvic surgery than the general population. We propose that a positive diagnosis of the condition may avoid the delay in diagnosis many patients experience. We conclude that, in Europe, there are significant unmet needs including lack of familiarity with irritable bowel syndrome, difficulties in diagnosis and lack of effective treatments for the multiple symptoms of the disorder. The development of pan-European guidelines for irritable bowel syndrome will benefit patients with this condition in Europe. (c) 2006 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:717 / 723
页数:7
相关论文
共 71 条
[1]  
*ACG, 2002, AM J GASTROENTEROL, V97, pS1
[2]  
*AGA PAT CAR COMM, 1997, GASTROENTEROLOGY, V112, P2118
[3]   Treatment of irritable bowel syndrome: a review of randomised controlled trials [J].
Akehurst, R ;
Kaltenthaler, E .
GUT, 2001, 48 (02) :272-282
[4]   Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial [J].
Atkinson, W ;
Sheldon, TA ;
Shaath, N ;
Whorwell, PJ .
GUT, 2004, 53 (10) :1459-1464
[5]   Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria [J].
Badia, X ;
Mearin, F ;
Balboa, A ;
Baró, E ;
Caldwell, E ;
Cucala, M ;
Díaz-Rubio, M ;
Fueyo, A ;
Ponce, J ;
Roset, M ;
Talley, NJ .
PHARMACOECONOMICS, 2002, 20 (11) :749-758
[6]  
Baretic M, 2002, COLLEGIUM ANTROPOL, V26, P85
[7]   Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome [J].
Bazzocchi, G ;
Gionchetti, P ;
Almerigi, PF ;
Amadini, C ;
Campieri, M .
DIGESTIVE AND LIVER DISEASE, 2002, 34 :S48-S53
[8]   The general practitioner's approach to irritable bowel syndrome: From intention to practice [J].
Bellini, M ;
Tosetti, C ;
Costa, F ;
Biagi, S ;
Stasi, C ;
Del Punta, A ;
Monicelli, P ;
Mumolo, MG ;
Ricchiuti, A ;
Bruzzi, P ;
Marchi, S .
DIGESTIVE AND LIVER DISEASE, 2005, 37 (12) :934-939
[9]   Treatment of irritable bowel syndrome with Chinese herbal medicine - A randomized controlled trial [J].
Bensoussan, A ;
Talley, NJ ;
Hing, M ;
Menzies, R ;
Guo, A ;
Ngu, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (18) :1585-1589
[10]  
Bertram S, 2001, J FAM PRACTICE, V50, P521